EU/U.S. Trade Pact Talks May Stumble Over Drug Regulation, Affordability
This article was originally published in The Pink Sheet Daily
Executive Summary
The EU Parliament’s health committee has highlighted regulatory pitfalls within TTIP, while civil society elements decry its lack of transparency and potential impact on health care affordability.
You may also be interested in...
EMA To Share Generics Data To Speed Access, But Pitfalls Remain
The EMA has announced that it is ready to share information on generic marketing authorizations with other regulators, which should speed market access, but industry remains concerned about patent linkage and discriminatory regulatory standards.
European Notebook: Agreements On Sovaldi, Olysio Pricing; Drug Shortages Increase; Rawlins Returns As Regulator
Patient access to the new generation of hepatitis C therapies is set to improve in Europe as pricing negotiations conclude, but concerns increase that a number of other marketed drugs are suffering supply shortages.
European Commission May Pursue More Antitrust Actions Against Pharma
The EC is scrutinizing pharma practices that may delay generic entry and advocating changes in the patent system.